Fiche centre
Northwest Clinical Research Center
Bellevue — United States
Essais liés20clinical trials
VilleBellevuelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06540833
Essais cliniques associés
20| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Piromelatine 20 mg | Alzheimer | Phase 2/3 | NCT05267535 | Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease | TERMINATED |
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Donanemab | Alzheimer | Phase 3 | NCT04437511 | A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) | ACTIVE_NOT_RECRUITING |
| KarXT | Alzheimer | Phase 3 | NCT06585787 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | RECRUITING |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03235479 | Safety and Efficacy Study in Adult Subjects With Acute Migraines | COMPLETED |
| Galcanezumab | Migraine | Phase 4 | NCT05127486 | CHALLENGE-MIG — A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| ITI-1284 | Alzheimer | Phase 2 | NCT06540833 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT03461757 | Trial in Adult Subjects With Acute Migraines | COMPLETED |
| sumatriptan nasal powder | Migraine | Phase 3 | NCT03338920 | Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents | TERMINATED |
| Dihydroergotamine | Migraine | Phase 3 | NCT04940390 | SUMMIT — A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine | COMPLETED |
| LHP588 | Alzheimer | Phase 2 | NCT06847321 | Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Rimegepant (PF-07899801) | Migraine | Phase 3 | NCT04743141 | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT02614261 | REGAIN — Evaluation of Galcanezumab in the Prevention of Chronic Migraine | COMPLETED |
| Rimegepant/BHV3000 | Migraine | Phase 3 | NCT04649242 | Randomized Study in Children and Adolescents With Migraine: Acute Treatment | RECRUITING |
| Rimegepant | Migraine | Phase 2/3 | NCT03266588 | Open Label Safety Study in Acute Treatment of Migraine | COMPLETED |